Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The prevalence of hypozincemia is high among patients with chronic kidney disease (CKD). Some observational studies have shown that non-dialysis CKD patients with hypozincemia have a higher risk of kidney failure events. However, these causal relationships have not been demonstrated in interventional studies.
This was a multicenter, open-label, randomized controlled trial conducted in Japan. Patients aged ≥20 years with eGFR <60 mL/min/1.73 m² and serum zinc concentration <60 µg/dL were randomly assigned 1:1 to receive zinc acetate hydrate tablets (zinc group) or no supplementation (control group). Zinc acetate hydrate tablets were prescribed according to the dosage and administration described in the package insert. The primary endpoint was a composite outcome comprising initiation of renal replacement therapy, ≥40% decline in eGFR from baseline, doubling of serum creatinine, or all-cause mortality. The secondary endpoint was the between-group difference in annual eGFR decline (eGFR slope).
A total of 115 participants were randomized: 57 to the zinc group and 58 to the control group. The overall mean age was 73 ± 12 years, mean eGFR was 29.9 ± 13.5 mL/min/1.73 m², and median observation period was 23.8 months. The primary outcome occurred in 11 of 57 participants (19.3%) in the zinc group and 12 of 58 (20.7%) in the control group (hazard ratio, 0.90; 95% confidence interval [CI], 0.34 to 2.38). The eGFR slope was -0.8 mL/min/1.73m² per year in the zinc group and -1.8 mL/min/1.73m² per year in the control group, with a between-group difference of -1.2 (95% CI, -3.3 to 0.9) mL/min/1.73m² per year. Adverse events causally related to zinc acetate hydrate tablets occurred in 9 of 54 participants (16.7%) in the zinc group.
In patients with CKD, zinc supplementation did not reduce the risk of the composite event of end-stage kidney disease and all-cause mortality. (Funded by the Nobelpharma Co., Ltd., ZAK-CKD study: Japan Registry of Clinical Trials, Number: jRCTs061210030)
